Detalhe da pesquisa
1.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 383(24): 2345-2357, 2020 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32955174
2.
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Lancet Oncol
; 23(10): 1297-1307, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36063830
3.
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
Clin Cancer Res
; 29(1): 92-99, 2023 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36318705
4.
Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Target Oncol
; 16(5): 613-623, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34478046